Why Is MADRIGAL PHARMACEUTI (MDGL) Stock Down Today?
By the Top Tier Newswire AI Desk · July 30, 2026 at 9:41 AM ET · reviewed against 5 wire stories
MADRIGAL PHARMACEUTI (MDGL) is down -13.48% in the latest session. Our newswire has captured 5 stories on MDGL across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 61/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why MDGL stock is down today
MDGL stock fell 13.48% to $473.18 in early trading on July 31, 2026, following a mixed earnings report and unusual intraday weakness. The stock opened with a 1.9% gap down from the previous close and continued to decline throughout the session, reaching a low of $466.45. The sharp move reflects investor reaction to the company’s financial results and broader market dynamics.
What Happened
Madrigal Pharmaceuticals reported its Q2 2026 results on July 30, showing net sales of Rezdiffra at $364.3 million, a 71% increase year-over-year. GAAP EPS was -$1.99, which beat estimates by $0.65. The company also announced expanded patent protections and late-stage pipeline progress. However, the report included a one-time $25 million expense and continued unprofitability, with a trailing twelve-month net margin of -27.3%. The SEC 8-K filing confirmed the results and provided additional financial details.
Despite these developments, the stock opened below the prior close and quickly fell further. The session saw heavy selling pressure, with volume already reaching 0.2 million shares, or half of the 3-month daily average. The stock traded at a discount to its 52-week high of $615.00 and is now within the lower end of its 52-week range.
What The Data Shows
The stock’s intraday trajectory suggests a bearish sentiment, with the price falling sharply after the opening bell. Volume was elevated, indicating active participation from traders or investors reacting to the earnings report. In the broader context, Madrigal’s market cap stands at $12.4 billion, with trailing twelve-month revenue up 256.8% but earnings still negative. The recent insider sales by key executives, including the CEO and Chief Medical Officer, may have added to investor caution.
What To Watch
Madrigal Pharmaceuticals does not have an upcoming earnings date in the immediate future. Investors should monitor coverage breadth and analyst commentary for further signals on the stock’s direction.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
MDGL · Jul 30 session (5-min) · -10.40% vs prior close · updated 8:55 PM ETAI sentiment, last 36h · averaged over 5 stories · 61/100 bullish
The headlines behind the move
Story flow · 5 stories on the wire, last 36h · hover or tap a dot for the headline
11d agoMarketChameleonBULLISH 73Earnings
Madrigal’s Q2 2026 Results Highlight Surging Rezdiffra Adoption, Expanded Patents, and Pipeline Progress
July 30, 2026
Madrigal Pharmaceuticals reported a 71% jump in Q2 Rezdiffra sales and doubled its patient base from the prior year. With fresh IP protections and a late-stage pipeline addition, the company signals both momentum and long-term strategy in the fast-growing MASH market.
Second-quarter 2026 Rezdiffra ® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30,...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →